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Abstract
Neuronal Ceroid Lipofuscinosis (NCL), also known as Batten disease, is a group of genetically distinct lysosomal disorders
that mainly affect the central nervous system, resulting in progressive motor and cognitive decline primarily in children.
Multiple distinct genes involved in the metabolism of lipids have been identified to date with various mutations in this
family of diseases. There is no cure for these diseases but some new therapeutic approaches have been tested that
offer more hope than the standard palliative care. Many of the therapeutic advances require invasive procedures but
some progress in slowing the disease has been found and more options can be expected in the future. We also review
the literature on children with disease/conditions other than NCL for the non-invasive use, safety, and tolerability of a
lipid-lowering drug, gemfibrozil, as a potential treatment for NCLs. Gemfibrozil has shown efficacy in an animal model
of NCL known as CLN2 (late infantile classic juvenile) and has been shown to be safe for lowering lipids in children.
Among the 200 non-NCL children found in the published literature who were treated with gemfibrozil for NCL-related
problems, only 3 experienced adverse events, including 2 with muscle pain and 1 with localized linear IgA bullous
dermatitis. We conclude that gemfibrozil is safe for long-term use in children, causes minimal adverse events, is well
tolerated, and may delay the progression of NCLs. Gemfibrozil may potentially be an alternative to more invasive
therapeutic approaches currently under investigation and has the potential to be used in combination with other
therapeutic approaches.
Keywords: Batten disease, NCL, Gemfibrozil, Lipofuscinosis, Central nervous system, Lysosome biogenesis, TPP1, Lopid,
CLN2, Children

Background
Neuronal Ceroid Lipofuscinsosis (NCL), also known as
Batten disease, is a group of inherited neurodegenerative
diseases affecting approximately 1–4 children per
100,000 live births [1–4]. NCLs mainly affect children
and generally start with seizures and/or a loss of vision
at an early age followed by rapid motor and cognitive
decline leading to premature death.
NCLs are generally autosomal recessive, and the frequency of these diseases varies by genetic mutation and
by country. To date, over 400 different mutations are
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found in multiple genes [2, 3, 5]. A data-base contains
information on the specific mutations identified to date
(http://www.ucl.ac.uk/ncl).
Most of the proteins encoded by the mutated genes
are lysosomal, including soluble enzymes (CLN1/PPT1,
CLN2/TPP1, CLN10/CTSD, CLN13/CTSF) or a soluble
lysosomal protein (CLN5) [2]. One protein is also
present in the secretory pathway (CLN11). In addition,
there are trans membrane proteins (CLN3, CLN6,
CLN7/MFSD8, CLN8, CLN12/ATP132A) and two cytoplasmic proteins that associate peripherally with membranes (CLN4, CLN14). Two trans membrane proteins
(CLN6 and CLN8) localize in the endoplasmic reticulum
while others (CLN4/DNAJC5 and CLN14/KCTD7) are
cytoplasmic and associate with cell membranes.
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The functional substrates of these proteins are not
known, and the major functions of the trans membrane
proteins in general and in the disease etiology are unclear [6]. The age of onset, severity, and rapidity of progression differ for each of the mutations in these genes
and for the different mutations within each gene [2].
Thus, a complex family of related lipid storage diseases
with different genetic etiologies forms the NCL family.
Such diversity in the genes and in the gene mutations
can make finding a comprehensive therapeutic treatment
challenging for the largely unknown and complex
pathophysiology of the NCLs.

Therapeutic approaches for NCLs
There is no cure for NCLs at this time. The standard of
care is generally to minimize symptoms, especially seizures. Many new therapies are emerging and hopefully
some will halt or slow disease progression but none are
likely to reverse the damage [7–9]. Based on a systematic
search of the literature and clinicaltrials.gov, several approaches offer promising therapeutic strategies, including gene therapy, stem cell therapy, enzyme replacement
therapy, anti-inflammatories, and small molecules. All
are being tested on animal models and in some cases the
studies have progressed to early stage human trials. Natural and genetically modified mice and other animal
models, including large animals, such as pigs, sheep,
cows, and dogs, have greatly helped in determining
delivery mode, ability to cross the blood-brain-barrier,
dosing amount, frequency of dosing, and efficacy. Unfortunately at this time, the work is primarily experimental
and invasive in many cases but proof of concept and improved treatment regimens offer considerable hope. The
complexity and number of genes and mutations affected
is problematic in developing and testing new treatments.
Below are some examples of the types of therapeutic
approaches and their success to date. One can expect
many more treatment options with additional emerging
technologies.
Viral-mediated gene therapy for NCLs generally
involves the use of a viral vector carrying a normal form
of the mutated gene localizing in the central nervous
system [10–12]. When the virus enters the cells in the
brain, the cells then express normal copies of the mutated protein that are taken up by the nearby cells. This
approach is attractive because it offers the potential for a
lifelong cure that does not require multiple repeated
treatments. It therefore is less invasive for the patient
than other approaches. There are many additional
advantages to viral vectors, including their tropism for
certain cells. However, these vectors, particularly the
adeno-associated viruses, do induce an immune
response. Lentiviral vectors have a reduced immune
response but their integration can be non-specific and is
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limited to the site of injection [13]. One concern is the
lack of potential therapeutic efficacy for the lipid accumulation in organs outside of the brain if the vector is
delivered to the brain. Using TPP1-deficient dogs treated
with an adenoviral vector containing TPP1, it was found
that the protein was increased in both the heart and
spleen but not in the kidney or liver [14]. Additional
studies are needed to optimize the efficacy and reduce
the potential immune response issues for viral vectors.
Various animal models have been tested with adenoassociated viral vectors and increased survival along with
improved motor skills were observed [12]. Based on
these successful results, phase 1 safety trials (NCT
01161576, NCT01414985, and NCT00151216) of an
adeno-associated viral gene transfer vector for CLN2 in
the brain of children with late infantile NCL are ongoing, and 1 phase 1/2a (NCT02725580) for CLN6 with
scAAV9 has begun.
Enzyme replacement therapy involves preparing a
large amount of protein based on the normal version of
the mutated gene usually by recombinant methods and
injecting the recombinant protein (rhTPP1) into the tissues, namely the brain for CNL2 [15–21]. The disadvantages are that the blood-brain-barrier has to be
considered and there is a need for repeated injections.
Mice, dogs, and monkeys tested with various doses and
different routes of administration have provided positive
results and led to a clinical trial for late infantile NCL
(NCT01907087) that is now complete. It is exciting that
this trial has reported positive results for CLN2 protein
replacement and that the treatment with recombinant
TPP1 (also known as cerliponase alpha or Brineura) was
recently approved by the FDA. The treated patients
showed a significant efficacy in the disease rating scale
relative to that of natural history controls i.e. disease
progression was reduced in the treated children. The
disadvantages are that for this level of success, the patients had 1 site in their brain injected every other week
for 48 weeks. The procedure is not a cure and is invasive
and costly. Enzyme replacement therapy is likely to work
for the patients with the mutated and soluble lysosomal
proteins (CLN1/PPT1, CLN2/TPP1, CLN10/CTSD,
CLN13/CTSF, CLN5) but not for the patients with mutated trans membrane and membrane-associated proteins (CLN3, CLN4/DNA JC5, CLN 5, CLN6, CLN7/
MFSD8, CLN8, CLN14) [4]. Further studies on the dosing amount and frequency, penetration through the
blood-brain-barrier, etc. are needed for optimization of
enzyme replacement therapy for NCLs.
Small molecule therapy involves enhancing activity by
correcting signaling or cellular metabolic pathways and
includes drugs that may act as pharmacological chaperones, receptor modulators, and immune modulators or
reduce the amount of substrate [7, 8, 22, 23].
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Chaperones have the advantage that they are small, can
distribute widely, and can be taken orally [22, 23]. The
disadvantage is that such drugs will have limited use as
they act only on proteins where the mutation is not near
the active site but has caused a protein-folding problem.
The use of receptor modulators is potentially a powerful
approach, and improvement in the motor function of a
mouse model of CLN3 has been observed with an
AMPA antagonist [7, 24–26]. However, substrate reduction therapy with Cystagon has not been successful
(NCT00028262) in reducing disease progression [27].
Immune modulators are a logical approach as inflammation precedes the neurodegeneration observed in NCLs.
Several immune modulators have been tested without
success [28, 29]. A recent phase 2 trial (NCT01399047)
for CLN3 with mycophenolate given for 8 weeks has yet
to report the results. These small molecule therapies will
likely become relevant as advances are made in delivery
and in their use in other neurodegenerative diseases.
Stem cell therapy, including bone marrow cells, is
aimed at having the stem cells incorporate into tissues
and provide a source of non-mutated proteins. It is also
possible that the stem cells will regenerate the tissue that
has been damaged or lost. Stem cell therapy is thus attractive because it offers the potential to replace damaged or lost tissue in advanced patients. To date,
hematopoietic stem cell transplantation has shown no
efficacy in NCL patients [30, 31]. Neural stem cells have
also been tested in a mouse model of CLN2 and some
reduction in the storage of lipids was found [32]. Fetal
neural stem cells have been injected into two locations
in the brain as part of a safety and efficacy trial in
patients with advanced disease (NCT00337636).
Immunosuppression was used to reduce complications.
The results of the trial showed good tolerability and an
increased production of CLN2 enzyme but additional
studies are needed to optimize this approach for
reducing or reversing disease progression.
In summary, there are many different types of
approaches being used to develop therapeutics for the
NCL family of diseases. These studies have been aided
greatly by the use of small and large animal models of
the different diseases [33, 34]. The exciting success of
enzyme replacement therapy for CLN2 is a proof of
principal that replacing the mutated soluble and secreted
proteins will be effective and offers the families and children a treatment option. Marked progress is being made
with other treatment approaches, such as gene therapy
and stem cells, as well as with small molecules [8].
Furthermore, new technologies, such as gene editing
and new classes of treatments, are emerging that may
advance some of these treatments. Because of the
complex genetics of the NCLs, these existing approaches
may be limited in applicability to each condition. The
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devastating effects on young children are rapid, often
not immediately diagnosed so that the disease has progressed at the time of diagnosis in many cases, and the
invasive nature of the majority of these treatments can
deter the families from opting to try them. Recently, a
simple and safe lipid lowering drug, gemfibrozil, has
shown efficacy in cells and in an animal model and may
offer the patients a non-invasive option for treatment
either alone or in combination with other emerging
treatments [35–49].

Gemfibrozil (Lopid)
Gemfibrozil is a member of the fibrates group of drugs
that lower lipid levels [35]. It was originally shown to
lower lipids in animals in the 1960s and was approved
by the FDA in 1976 for human use to reduce serum
lipids. It reduces the levels of triglycerides, very lowdensity lipoprotein (VLDL, “bad cholesterol”), and lowdensity lipoprotein (LDL, “bad cholesterol”) and
increases high-density lipoprotein (HDL, “good
cholesterol”). Gemfibrozil is an activator of peroxisome
proliferator-activated receptor-alpha (PPARα), a nuclear
receptor important in the metabolism of fats (Fig. 1)
[36–40]. It also regulates adipose tissue differentiation. It
thus promotes the clearance of lipids [35]. A major advantage is that it is taken orally as a 600 mg tablet twice
a day before meals and has minimal side effects. In fact,
gemfibrozil has been found to have many additional effects on reducing inflammation, regulating oxidative
stress, promoting signal transduction, increasing myelination, etc. [40, 41] which have led to many past and
ongoing clinical trials in other disease pathologies
(www.clinicaltrials.gov).
The mechanism of action of Gemfibrozil on
lowering lipids
Fatty acids are metabolized in mitochondria and in peroxisomes. While short, medium, and long chain fatty
acids are metabolized in mitochondria, very long chain
fatty acids (VLCFAs) are chain-shortened in peroxisomes via peroxisomal β-oxidation. Gemfibrozil being
one of the prototype activators of PPARα stimulates peroxisomal β-oxidation by up-regulating the expression of
all three important peroxisomal β-oxidation enzymes
(acyl-CoA oxidase, 2-trans-enoyl-CoA hydratase, and
thiolase) via PPAR-α (Fig. 1) [39, 41]. Since VLCFAs are
major components of LDL and VLDL, a gemfibrozilmediated decrease in bad cholesterol (VLDL and LDL)
is directly correlated to increased catabolism of VLCFAs
in peroxisomes.
How does gemfibrozil modulate TPP1?
Gemfibrozil acts in two ways to increase TPP1 in cells
(Fig. 1). Gemfibrozil activates PPARα, which enhances
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Fig. 1 Scheme showing the dual mechanism of action of gemfibrozil

the mRNA and protein levels of transcription factor EB
(TFEB) by more than 10-fold and 6-fold, respectively, in
brain cells within 12 h [39]. TFEB then binds to the promoter of genes involved in lysosome biogenesis and activates their production [43–46]. TFEB can regulate
lysosomes due to its effects on the expression on lysosomal genes. All-trans retinoic acid has similar activity.
The combination of all-trans retinoic acid with gemfibrozil also enhances TFEB production within 12 h, and
lower doses of both compounds provided maximal activity in enhancing lysosome biogenesis in brain cells and
in cells derived from patients with CLN2/TPP1 [38].
Gemfibrozil also binds to the retinoid X receptor-α
(RXRα), which binds to PPARα thereby up-regulating
the expression of TPP1 in brain cells via the PPARα/
RXRα heterodimer. Increased TPP1 activity has been
observed in a variety of neuronal cells and fibroblasts
treated with gemfibrozil but not in iPSC cells (Table 1)
[38, 47]. Based on these dual activities, gemfibrozil has
potential for therapeutic applications in the NCLs.

Studies on cells treated with gemfibrozil
Various cells in culture have been treated with gemfibrozil (38,47,48) (Table 1). The effect of gemfibrozil on
Cln2 mRNA, protein expression, and TPP1 activity has
been studied in primary mouse neurons and in astrocytes and in human astrocytes, and neuronal cells from

different regions of the brain (cortex, hippocampus, striatum, and cerebellum). Gemfibrozil increased the
mRNA for Cln2 with a maximum increase at 24 h in
mouse primary astrocytes [38, 39]. Interestingly the
mRNA for other lysosomal genes, such as Cln1 and
Cln3, were also increased by gemfibrozil. Increased
TPP1 protein was observed inside the cells as well.
Neuronal cells and human astrocytes also showed a
similar response with increased mRNA and protein that
was validated by either western blot, immunofluorescence, and/or by a TPP1 activity assay [38]. The effect of
gemfibrozil on TPP1 mRNA was evaluated in wild type,
PPARα deficient, and PPARβ deficient astrocytes isolated
from cells from wild type and genetically modified mice
[39]. Interestingly, gemfibrozil did not increase Cln2
mRNA levels in the cells from the PPARα knock out
(KO) mice whereas the increase in Cln2 mRNA was
seen with gemfibrozil treatment of cells from both wild
type and PPARβ KO mice. Immunofluorescence, western
blot, and an enzyme activity assay confirmed the lack of
Cln2 mRNA up-regulation by gemfibrozil in the cells
isolated from the PPARα KO mice [38]. Similar studies
were done with siRNA-treated cells where there was no
increase in TPP1 with gemfibrozil, and this study further
demonstrated the role of RXRα in regulating the expression of TPP1 mRNA. These studies confirm the involvement of PPARα/RXRα in the gemfibrozil-mediated
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Table 1 Effect of gemfibrozil on cells and on animals
Treatment

Effect

Reference

Mouse & human primary astrocytes

gemfibrozi 25 μm

↑CLN2 mRNA ↑TPP1 protein

38, 39

Mouse neurons from cortex,
striatum & hippocampus

gemfibrozil 25 μm

↑TPP1 protein

38

Lymphoblastic cells from
CLN3 patients

gemfibrozil 25 μm

↑viability ↑autophagy recovery ↑autophagy genes

48

No effect on TPP1

47

Cells in vitro

Human IPS models CLN2 and CLN3 mutations gemfibrozil 25 µm
Animals
Mouse

oral gemfibrozil 7.5 mg/kg for 21 d ↑TTP1 in astrocytes, cortical neurons, & non
38
neural cells of dentate gyrus & CAI of hippocampus

Mouse KO LINCL

oral gemfibrozil 7.5 mg/kg for 21 d ↑longevity, ↑motor retention, ↓apoptosis,
↑anti-inflammatory molecules

49

d = days

increase in both Cln2 mRNA and TPP1 protein [38]. It
was concluded that gemfibrozil and retinoic acid recruit
both PPARα and RXRα to the RXR-binding site of the
Cln2 gene promoter.
Some studies have been done on cells derived from
NCL patients and models (Table 1) [48, 49]. Lymphoblasts isolated from control and NCL patients were
investigated for the effect of gemfibrozil on apoptosis,
depolarization of the mitochondrial membrane, and
defective autophagy [49]. NCL (CLN3) lymphoblast cell
viability to normal levels was restored by gemfibrozil in
NCL patient-derived lymphoblasts via decreased apoptosis. Furthermore, the high level of membrane potential
depolarization of NCL patient-derived lymphoblasts was
restored to normal levels by gemfibrozil, and defective
autophagy was normalized by gemfibrozil. These findings suggest that gemfibrozil may have a therapeutic
effect by multiple mechanisms for NCL patients [39, 40].

Studies on animals treated with gemfibrozil
The effect of gemfibrozil has been evaluated in a newly
created mouse model of CLN2/TPP1 of NCL (Figure 2)
[49]. This model was created by knocking out the gene
for TPP1. The mice develop progressive motor dysfunction and die prematurely. A dose of 7.5 mg/kg body
weight of gemfibrozil increased survival by several
weeks to 172 days over that observed with vehicle
alone, 123 days. Furthermore, the mice showed improved motor functions over the controls. Both SOCS3
and IL-Rα are anti-inflammatory factors that are increased with gemfibozil treatment. The anti-apoptotic
molecule phospho-Bad also increased and was coincident with decreased neuronal loss based on a TUNEL
assay. Finally, a decrease in storage materials in the
motor cortex of the brain was observed in the
gemfibrozil-treated cln2 knock out mice as compared

with the untreated knock out mice [49]. Interestingly,
since these genetically-modified mice lack the cln2
gene, gemfibrozil is likely not working by increasing
TPP1 expression but rather via lysosome biogenesis
and other activities. The findings suggest that gemfibrozil can delay the progression of neurodegenerative
decline in an animal model by multiple mechanisms.
Clearly optimizing the dose and frequency of dosing
may further improve the outcome with the animals.
The data also suggest that the neuroprotection by gemfibrozil may be applicable to treating children with
CLN2/TPP1 NCL and possible other genetic variants of
the NCLs [48, 49].
When wild type and PPARα and PPARβ KO mice were
analyzed for the effect of gemfibrozil on TPP1

Fig. 2 Summary of the effects of gemfibrozil on the CLN2 knock
out mouse
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expression, gemfibrozil markedly increased TTP1 protein expression in the cells of the brains of the wild type
and PPARβ KO mice but not in the PPARα KO mice
[38, 39]. These findings again demonstrate the involvement of PPARα in the gemfibrozil-mediated increase in
TTP1 (38). Furthermore, the Cln2 gene contains an
RXR-binding site, and all-trans retinoic alone can increase TTP1 expression. The studies further confirm
the mechanism of action of gemfibrozil in vivo and
demonstrate the role of the PPARα/RXRα heterodimer
in its activity.

Safety of gemfibrozil: Studies with children
treated with gemfibrozil
Having been approved for human use in 1976, gemfibrozil has a long history of safety and tolerability in adults
as a lipid-lowering agent. It has also been used with children for various indications (Table 2). In a small study
with 12 children aged 5–17 years who had hyperlipidemia with persistent nephrotic syndrome, gemfibrozil
given for 4 months to 7 of the patients (5 were controls)
was found to be effective in improving the lipoprotein
profile of the nephrotic children [50]. Besides efficacy,
gemfibrozil had no side effects, and renal function and
urine protein excretion in this fragile population were
not affected by the treatment. Gemfibrozil was also
given in 2 doses 12 h apart in a study with 97 neonates
(49 treated and 48 control) of at least 34-week gestation
with non-hemolytic jaundice. While there was no change
in the need and duration of phototherapy with the gemfibrozil, it was noted that there were no side effects in
the preterm and term neonates [51]. In another pilot
study on 47 pediatric patients with metabolic syndrome,
a dose of 1200 mg/day gemfibrozil for 8 months significantly lowered the triglyceride levels and raised the HDL
levels [52]. Two of the patients had muscle pain associated with the treatment but no other safety issues were
found. Muscle pain was reported as a probable adverse
event in adults. Further, it has been suggested that
fibrates should be considered for children with obesity-
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related hyperlipidemias [53]. Two siblings with familial
chylomicronemia syndrome were treated from birth
(oldest child age 7 in the study) and at 6 months of age
(younger child age 4 in the study) with 300 mg gemfibrozil twice per day [54]. At 7 and 3.5 years respectively,
there were no side effects from the gemfibrozil, and the
risk of acute pancreatitis, a complication of hyperlipidemia, was significantly reduced. There was one case report of an age 13 female patient who developed linear
IgA bullous dermatitis on her areola after 3 weeks on
gemfibrozil, which resolved with drug withdrawal and
steroid treatment [55]. Although side effects have been
reported in adults taking gemfibrozil (Table 3), these are
generally uncommon and rarely severe.
These studies demonstrate that gemfibrozil was well
tolerated and was safe for use in children even with ongoing disease processes. Based on the known drug interactions of gemfibrozil (Table 4), children with NCL
should not be expected to experience problems. However, with gemfibrozil treatment there may be a potential
reduction in the effectiveness of the anti-convulsive therapies that should be monitored. The off label use of
gemfibrozil in ill children over a range of ages, doses,
and durations suggests that gemfibrozil can be expected
to be safe for use in children with lipid storage diseases.

Summary and conclusions
There are several advantages for use of gemfibrozil in
children with lysosomal storage diseases, NCLs, and in
particular late infantile batten disease CLN2/TPP1.
Gemfibrozil is an oral drug that is not invasive and has
few side effects in adults and in children. Gemfibrozil
has multiple modes of action, and the mechanisms of action are known for some of the activities, such as its
ability to increase TPP1 mRNA, protein, and activity, reduce inflammation, increase myelination, and increase
lysosome biogenesis [39, 40]. Gemfibrozil can also affect
various signaling pathways involved in switching off Thelper cells, cell-to-cell contact, migration, apoptosis,
oxidative stress, and inflammation. Finally, using knock

Table 2 Safety of gemfibrozil in children
Age

Dose (duration)

Purpose

Effect

Side effects (reference)

Children with metabolic Syndrome, n = 47

600 mg 2 x /day
(8 months)

reduce lipids

↓triglycerides
↑HDL

1AE muscle pain
n = 2 (52)

Late preterm & term neonates with jaundice
n = 97 (49 active, 48 placebo)

60 mg/kg 2 doses
(1 day)

reduce light therapy time,
decrease bilirubin

no effect

none
(51)

Infants with Chylomicronemia* Syndrome, n = 2

300 mg 2 x /day
(3, 7 years)

improve jaundice

↓pancreatitis

none (54)

Children with hyperlipidemia & nephrotic
syndrome, n=12 (7 active, 5 placebo)

150 mg 2 x/day
(4 months)

reduce lipids

↓cholesterol
↓triglycerides

none (50)

Age 13 female n = 1

3 weeks

reduce lipids

NA

LABD (55)

*Siblings started gemfibrozil at birth and at 6 months, respectively
LABD, linear IgA bullous dermatitis
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Table 3 Events related to treatment with gemfibrozil

General:

Causal relationship

Causal relationship

Probable

Not established

weight loss

Cardiac

extrasystoles

Gastrointestinal

cholestatic jaundice
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Table 4 Drug interactions with gemfibrozil
Concomitant
medication

Cautions

HMG-CoA
Reductase Inhibitors

risk of myopathy and rhabdomyolysis

Anticoagulants

warfarin dosage should be reduced

CYP2C8 Substrates

drugs metabolized CYP2C8 (e.g., dabrafenib,
loperamide, montelukast, paclitaxel, pioglitazone,
rosiglitazone) may be required to reduce

OATP1B1 substrates

substrates of OATP1B1 (e.g., atrasentan,
atorvastatin, bosentan, ezetimibe, fluvastatin,
glyburide, SN-38 [active metabolite of irinotecan],
rosuvastatin, pitavastatin, pravastatin, rifampin,
valsartan, olmesartan) may be required to reduce

decreased libido

Bile Acid-Binding
Resins

resin-granule drugs such as colestipol (5 g)
are recommended at 2 or more hours apart

depression

Colchicine

myopathy, including rhabdomyolysis in
chronic administration of colchicine

pancreatitis
hepatoma
colitis

Central Nervous
System

dizziness

confusion

Somnolence

convulsions

Paresthesia

syncope

peripheral neuritis

headache
Eye

blurred vision

Genitourinary

impotence

SPC of LOPID issued March.2016

retina edema
decreased male fertility
renal dysfunction

Musculoskeletal

myopathy
myasthenia
myalgia
painful extremities
arthralgia
synovitis
rhabdomyolysis

Clinical Laboratories increased creatine

positive antinuclear
antibody

Phosphokinase
increased bilirubin
increased liver
transaminases (AST, ALT)
increased alkaline
phosphatase
Hematopoietic

anemia

thrombocytopenia

leukopenia
bone marrow hypoplasia

out animal models of CLN2/TPP1, gemfibrozil was
found to prolong the lifespan of the animals, decrease
lipid accumulation in the motor cortex, delay the loss of
mobility, and increase certain genes involved in antiinflammation and in anti-apoptosis [49]. This neuroprotective effects combined with the potential increases in
TPP1 enzyme levels and in biogenesis of lysosomes
suggest that gemfibrozil will have some benefit in treating early stage children with CLN2/TPP1 and possibly
with other genetic forms of NCLs. The oral administration is particularly attractive because it is non-invasive
and the safety is well documented. Gemfibrozil could be
used alone or combination with some of the emerging
treatments for these devastating genetic diseases in children. One possible limitation might be weight loss that
will need to be monitored since NCL patients have
weight gain issues.
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